Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Price Target of $10.00 According to Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several brokerages have issued reports on AUTL. HC Wainwright began coverage on shares of Autolus Therapeutics in a research report on Monday, November 2nd. They set a “buy” rating for the company. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. Finally, Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $1.28 on Monday. The firm has a 50-day moving average of $1.80 and a 200-day moving average of $1.66. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. The stock has a market cap of $340.68 million, a PE ratio of -1.21 and a beta of 2.32. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The business had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. On average, sell-side analysts anticipate that Autolus Therapeutics will post -0.76 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently added to or reduced their stakes in AUTL. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics in the 2nd quarter valued at $26,625,152. Cetera Investment Advisers grew its holdings in Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after buying an additional 29,324 shares in the last quarter. Alphabet Inc. acquired a new position in Autolus Therapeutics in the 2nd quarter valued at $1,117,000. Privium Fund Management B.V. grew its holdings in Autolus Therapeutics by 29.2% in the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock valued at $911,000 after buying an additional 106,060 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its position in Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after buying an additional 11,197 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.